Granules Is Deleveraging While Spending on Expansion; Is Cash Flow Replacing Debt as Its Funding Engine?
Granules India has sharply reduced its net debt while continuing to invest in complex generics, manufacturing capacity, and its peptide CDMO platform. The company generated strong operating cash flow in Q1 FY27 even as leverage neared zero. This article examines whether improved cash generation is sufficient to support the company’s planned capex without reversing its balance-sheet progress.
Granules India was trading at around ₹838 per share, with a market capitalization of approximately ₹22,856 crore. The stock’s 52-week range was ₹520–₹924, while its trailing P/E was around 35x.
Sharp Debt Reduction Is Cutting Interest Costs
The company’s balance sheet has strengthened significantly, with consolidated net debt falling from ₹402.1 crore at the end of FY26 to ₹101.2 crore in Q1 FY27. This brought net debt/EBITDA down to just 0.07x, prompting management to describe the business as effectively debt-free.
The improvement is already translating into lower finance costs. Finance cost declined to ₹21.1 crore in Q1 FY27 from ₹32.7 crore a year earlier, allowing a greater share of operating earnings to flow through to profit after tax. Lower debt servicing requirements also provide greater flexibility to deploy cash towards research, complex generics, new technology platforms, and other growth investments.
Also read: RailTel Corporation of India wins ₹48.40 Crore contract to establish vocational labs in Odisha
Operating Cash Flow Surged as Working Capital Improved
Granules generated ₹387.4 crore of consolidated operating cash flow in Q1 FY27, nearly four times the ₹100.3 crore generated in Q4 FY26. The improvement was supported by better working-capital management, particularly a reduction in receivables from the US business, while broadly stable sequential revenue meant the company required relatively limited additional working capital. Consolidated working capital as a percentage of sales also improved marginally to around 29% in Q1 FY27, compared with 30% in both Q1 FY26 and Q4 FY26. This improvement is significant because stronger cash conversion allows the company to turn a greater portion of reported earnings into funds available for business requirements.
₹600 Cr FY27 Capex Plan Remains Intact
Deleveraging has not come at the cost of reducing investment. Management has maintained its FY27 consolidated capex guidance of around ₹600 crore, even after spending approximately ₹89 crore in Q1. Capital spending is being directed towards manufacturing capabilities and strategic growth projects, while the Genome Valley investment cycle has largely been completed.
Also read: Raymond Realty shares in focus after reporting strong Q2 FY27 pre-sales of ₹902 Crore
This creates an interesting financial setup. The company is simultaneously reducing debt and continuing to invest heavily in future capacity. The important question is whether operating cash generation can remain strong enough to support the remaining investment without requiring a fresh increase in borrowings.
Cash Generation Supports Higher-Value Growth
The company’s financial improvement is happening at the same time as it increases investment in businesses that management expects to drive future growth.R&D spending increased 30% YoY to ₹88 crore, equivalent to around 6% of sales. Management expects R&D spending to remain around 5.5–6% of revenue, with the majority directed towards complex generics.
Complex generics now account for approximately 50% of finished-dosage sales, up from around 39% a year earlier.The company is also investing in its peptide CDMO platform, where quarterly profitability can remain volatile because revenues are project-driven and costs can be incurred well before projects are monetised. This makes the deleveraging more meaningful. The company is not reducing debt by cutting investment in future businesses; it is trying to fund that transition from internally generated cash.
Also read: Should you invest in markets if you are not getting Returns? | Stock Investing 101
Returns Could Improve as Capacity Ramps Up
The company’s return on capital employed also improved to around 18% in Q1 FY27 from 17.6% in Q4 FY26. Management expects returns to improve further as the Genome Valley facility and peptide platform scale up.
That is an important part of the capital-allocation story. The company is spending heavily today, but the objective is for those investments to generate higher earnings and returns as utilisation increases.The success of this strategy will therefore depend on how quickly the new assets move from investment phase to productive phase.
The Key Risk: Can Deleveraging Continue?
The current numbers are encouraging, but there is an important caveat.Q1 operating cash flow of ₹387.4 crore was unusually strong relative to quarterly capex, and part of that improvement came from working-capital movements. It would be premature to assume that the company can generate similar cash flow every quarter.
At the same time, the company still plans around ₹600 crore of capex for FY27. A significant portion of that spending is yet to happen.Therefore, the next few quarters will show whether cash generation remains strong enough to fund expansion while keeping net debt close to current levels.
Future Perspective
Granules’ financial strategy is becoming increasingly visible in the numbers: ₹101.2 crore of net debt, 0.07x net debt/EBITDA, ₹387.4 crore of operating cash flow and ₹89 crore of quarterly capex.
At the same time, the company is increasing R&D spending, expanding complex generics and investing in its peptide platform rather than slowing down its growth plans.
The next test is simple: can the company maintain strong cash conversion while executing around ₹600 crore of FY27 capex? If it can, the business could continue funding a larger part of its expansion internally while keeping leverage low. The numbers to watch will be operating cash flow, capex, working capital, net debt and ROCE over the next few quarters.
